Just as 2019 saw clinical success and setbacks, new partnerships and acquisitions to bolster future pipelines and combination approaches: the 2020 NASH landscape is about to change, and bring with it a series of new challenges.
The 3rd NASH Summit Europe is the only niche, discussion orientated conference solely dedicated to addressing these hurdles, assessing clinical appetite and advancing NASH pipelines towards success.
Across 3 packed days, join Europe’s NASH stakeholders as they lead directive discussions, share actionable insights and analyse the next 12 months of NASH drug development through a tighter lens.
- Address pharma-physician disconnect in Europe with the EMA
- Understand considerations from European Health Technology Assessment Bodies when assessing the value of medicines for NASH with NICE
- Review regulatory guidance for NASH with compensated cirrhosis with the FDA
Join 80+ other NASH drug developers to navigate solutions for these and 10+ other rate limiting factors as the first NASH therapies receive approval.
* Early booking rates end Friday 23rd August *
Book now to secure your place and save £300!
World Class Speaking Faculty
Giampiero “GP” Carlo
Head of Brand: Cotadutide, Cardiovascular, Renal & Metabolism (CVRM)
AstraZeneca
A Glimpse Of What to Expect
"This was unlike any scientific meeting I have ever been to. Everyone who attended was interested in some aspect of drug development for NASH. I truly enjoyed the "applied science" focus of the meeting as it helped me where I most needed the help. The opportunity to network and learn informally in the poster session and during receptions was excellent."
Proud To Partner With
Other Events In The Series
